Follow Us
Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Part Two of a Two-Part Article
In last month's newsletter, we began discussion of a defamation claim brought against two attorneys who took to the airwaves to publicize their client's complaints against a hospital and its owner. The defendants in that matter sought redress for what they claimed were untrue, and very unflattering, statements, but the attorneys moved for dismissal of the claims. We continue here with the court's reasons for granting the attorneys' motion.
In last month’s newsletter, we began discussion of a defamation claim brought against two attorneys, Brian Kabateck and Robert Hutchinson, who took to the airwaves to publicize their client Mary Cavallieri’s complaints against a hospital and its owner, Michael D. Drobot. The defendants in that matter sought redress for what they claimed were untrue, and very unflattering, statements, but the attorneys moved for dismissal of Drobot’s claims in accordance with California’s anti-SLAPP (anti-Strategic Lawsuit Against Public Participation) statute (Code Civ. Proc., § 425.16, subd. (b)). We continue here with the court’s reasons for granting the attorneys’ motion.
*May exclude premium content
Defeating Certification of “No-Injury” Consumer Protection Class Actions
By Steven P. Benenson
In the past several years, plaintiffs’ firms have threatened or brought class actions against different companies under New Jersey’s Truth-in-Consumer Contract Warranty and Notice Act (TCCWNA). Here's what you need to know.
Maximizing Future Medical Damages in Paralysis Cases
By Mitch Warnock
When you take a catastrophic injury case involving paralysis, it is important to have a thorough understanding of the problems and pitfalls. In this article, the author explores, from personal experience, the different types of future expenses the client can expect to incur.
Genetic Labeling: Legal Uncertainty for Pharma Product Liability
By Shannon E. McClure and Whitney Mayer
The FDA’s recent approval of 23andMe’s direct-to-consumer genetic test to identify genes associated with 10 common diseases and disorders could result in a widespread expansion of patients armed with individualized health information. This expansion of genetic information in the hands of consumers potentially impacts regulatory and litigation issues for pharmaceutical companies.
By ljnstaff
Discussion of major rulings out of Texas and California.
Copyright © ALM Global, LLC. All Rights Reserved.
